Table 2. Immune responses and laboratory data of patient groups.
| Parameters (mean±s.d.) (n) | HCs (n=39) | HCC− (n=78) | HCC+ (n=61) | P* |
|---|---|---|---|---|
| M30 (U l−1) | 185±133 | 1179±856 | 1181±870 | 1.00 |
| TPO (pg ml−1) | 501±106 | 163±247 | 226±210 | <0.001 |
| CCL2 (pg ml−1) | 179±71 | 245±689 | 129±192 | 0.008 |
| Median | 172 | 111 | 80 | |
| CCL3 (pg ml−1) | 70±199 | 51±370 | 10±54 | 0.13 |
| CCL4 (pg ml−1) | 66±32 | 101±484 | 170±378 | <0.0001 |
| Median | 63 | 37 | 88 | |
| CCL5 (ng ml−1) | 11±11 | 2.0±4.8 | 3.6±5.5 | <0.0001 |
| CXCL5 (pg ml−1) | 766±540 | 118±159 | 230±301 | <0.001 |
Abbreviations: CCL=C-C chemokine ligand; CXCL=C-X-C chemokine ligand; M30=Caspase-cleaved cytokeratin 18 fragment; TPO=thrombopoietin. Mann–Whitney U-test was used. P-values<0.05 after Bonferroni correction were considered significant and are in bold. *P value of HCC+ vs HCC− patients.